Skip to main content

Table 1 Clinical characteristics of patients by groups

From: Impact of the faecal immunochemical test on colorectal cancer survival

 

GROUP 1 N = 279

N (%)

GROUP 2 N = 1248

N (%)

p

AGE (years)

  ≤ 49

13 (4.7)

52 (4.2)

 

 50–69

74 (26.5)

423 (33.9)

0.06

  ≥ 70

192 (68.8)

773 (61.9)

 

SEX

 (% men)

63%

59%

0.17

SITE*

 Rectum

67 (24.1)

300 (24.0)

 

 Distal colon

115 (41.2)

564 (45.2)

0.31

 Proximal colon

94 (33.7)

364 (29.2)

 

 Unknown

3(1.0)

20(1.6)

 

HISTOLOGY

 Adenocarcinoma

267 (95.7)

1184 (94.9)

 

 Mucinous adenocarcinoma

7 (2.5)

41 (3.3)

0.8

 Others**

5 (1.8)

23 (1.8)

 

STAGE

 Stage I

51 (18.3)

170 (13.6)

 

 Stage II

92 (33.0)

398 (31.9)

 

 Stage III

64 (22.9)

308 (24.7)

0.04(***)

 Stage IV

72 (25.8)

370 (29.7)

 

 Unknown

2(0.1)

 
  1. (Group 1: with positive faecal immunochemical test results in the previous 12 months/Group 2: patients that either did not performed any FIT in the previous 12 months before diagnosis or display a negative FIT) * Proximal colon: caecum, ascending colon, hepatic flexure or transverse colon; Distal colon: splenic flexure, descending colon and sigmoid colon. **Others: signet ring cell carcinoma, neuroendocrine carcinoma, squamous cell carcinoma. ***Chi square for linear trend